This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-22. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Charles David Sherrill is a professor of chemistry and computational science and engineering at Georgia Tech working in the areas of theoretical chemistry, computational quantum chemistry, and scientific computing. His research focuses on the development and application of theoretical methods for non-covalent interactions between molecules. He is the lead principal investigator of the Psi open-source quantum chemistry program.
Headspace gas chromatography uses headspace gas—from the top or "head" of a sealed container containing a liquid or solid brought to equilibrium—injected directly onto a gas chromatographic column for separation and analysis. In this process, only the most volatile (most readily existing as a vapor) substances make it to the column. The technique is commonly applied to the analysis of polymers, food and beverages, blood alcohol levels, environmental variables, cosmetics, and pharmaceutical ingredients.
== Distribution == Rotheca myricoides is native to mountains from Eritrea to South Africa. It is native to Angola, Botswana, Burundi, Caprivi Strip, Democratic Republic of the Congo, Djibouti, Eswatini, Eritrea, Ethiopia, Kenya, KwaZulu-Natal, Malawi, Mozambique, Namibia, Northern Provinces, Rwanda, Somalia, Sudan, Tanzania, Uganda, Zambia, and Zimbabwe. It was introduced to Trinidad-Tobago, Australia, and Brazil.
In addition, sexual wellbeing is often lower in women with PMOS. Women with PMOS are about three times more likely to develop endometrial cancer. This is linked to lack of periods and lower levels of sex hormone-binding globulin (SHBG) and progesterone. Women with PMOS more often have sleep apnea, particularly if obesity is present.
Sources: en.wikipedia.org
== History == Originally home to the Ojibwe, Winnebago, and Dakota people, Cold Spring was platted in 1856, and named for the many springs near the original town site. A post office has been in operation at Cold Spring since 1857. German-speaking Catholics settled in the area, lured by the Slovenian missionary priest Francis Xavier Pierz, who had submitted letters and advertisements to the major German-language newspapers across the U.S., such as Der Wahrheitsfreund (The Friend of Truth), and in Europe, urging "good, pious" German Catholics to come to the Sauk River Valley, which he called a "land flowing with milk and honey" and safe from disease and anti-Catholic oppression. During the grasshopper plagues of the 1870s, Assumption Chapel, also known as the Grasshopper Chapel, was built in petition for relief from the locusts. Cold Spring has three properties on the National Register of Historic Places: the John Oster House and Ferdinand Peters House, both built in 1907, and the Eugene Hermanutz House, built in 1912. The city was thrust in the national spotlight on September 24, 2003, when then 15-year-old Jason McLaughlin shot and killed two classmates in the Rocori High School shooting.
Osteocalcin, also known as bone gamma-carboxyglutamic acid-containing protein (BGLAP), is a small (49-amino-acid) noncollagenous protein hormone found in bone and dentin, first identified as a calcium-binding protein. Because osteocalcin has gla domains, its synthesis is vitamin K2–dependent. In humans, osteocalcin is encoded by the BGLAP gene. Its receptors include GPRC6A, GPR158, and possibly a third, yet-to-be-identified receptor. There is evidence that GPR37 might be the third osteocalcin receptor.
Retinyl acetate (also called vitamin A acetate or all‑trans‑retinol acetate) is a synthetic, fat‑soluble acetate ester of retinol often used to supply vitamin A in food fortification, dietary supplements, and topical cosmetic products. Because the acetyl group protects the alcohol functionality, the compound is markedly more stable to heat, oxygen and light than free retinol, yet is rapidly hydrolyzed in the human intestine to active retinol after ingestion. Commercially, retinyl acetate is the second most common retinyl ester after retinyl palmitate.
Calcitonin is a hormone that triggers a short-term drop in calcium and phosphate levels in the blood. In humans, it is encoded by the gene CALCA. It is a 32 amino acid peptide hormone secreted by parafollicular cells (also known as C cells) of the thyroid (or endostyle) in humans and other chordates in the ultimopharyngeal body. By reducing blood calcium (Ca2+), it opposes the effects of parathyroid hormone (PTH). Its importance in humans has not been as well established as its importance in other animals, as its function is usually not significant in the regulation of normal calcium homeostasis. It belongs to the calcitonin-like protein family. Historically calcitonin has also been called thyrocalcitonin.
Because of the potentially hazardous consequences, the concomitant use of tizanidine with fluvoxamine, or other potent inhibitors of CYP1A2, should be avoided. When a beta-blocker is required, atenolol, pindolol and, possibly, metoprolol may be safer choices than propranolol, as the latter's metabolism is seriously, potentially dangerously, inhibited by fluvoxamine. Indeed, fluvoxamine may increase propranolol blood-levels by five-fold. Clomipramine increases fluvoxamine levels and, conversely-likewise, fluvoxamine increases clomipramine levels (thereby its serotonergic potential) and inhibits its metabolism to its strongly-noradrenergic metabolite, norclomipramine.
Sources: en.wikipedia.org
== Medical uses == In the United States, temozolomide is indicated for the treatment of adults with newly diagnosed glioblastoma concomitantly with radiotherapy and subsequently as monotherapy treatment; or adults with newly diagnosed or refractory anaplastic astrocytoma. In the European Union, temozolomide is indicated for adults with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment; or children from the age of three years, adolescents and adults with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. Temozolomide is normally prescribed in cycles, with the patient taking the medication once a day for five days, then going 28 days without it. In the UK, NHS guidelines recommend that the drug is only used for six cycles. It is considered unusual for patients to continue taking the drug past 12 cycles. Temozolomide is also used to treat aggressive pituitary tumors and pituitary cancer.
==== Productivity and adoption rates ==== While experimental studies show substantial productivity improvements for workers assisted by AI, such as software developers completing tasks 26% faster and mid-level professionals spending 40% less time on routine writing, these gains have not yet translated into economy-wide productivity growth in the UK. McKinsey & Company describes this as the "new productivity paradox", noting that over the past year, the largest contributions to UK productivity growth came from sectors with relatively low AI exposure, such as retail and facilities management. This paradox is partly explained by adoption patterns. A March 2026 survey by the British Chambers of Commerce (BCC) found that while AI adoption among SMEs had accelerated to 54% (up from 25% in 2024), most firms were using generic tools (like chatbots) rather than deeply integrated, bespoke systems. Furthermore, a 2026 global study by PwC showed that nearly 74% of AI's economic value is being captured by just 20% of organisations, being those that use AI to reinvent business models and pursue growth, rather than merely seeking cost reductions.
Taylor (2015) reported that the perceived self-efficacy and perceived helplessness subscales tended to estimate scores reliably across levels of the latent variables except among respondents with exceptionally low levels of perceived helplessness and exceptionally high levels of perceived self-efficacy. Finally, much less is known about the reliability of scores from the 4-item form.
0.063 in or 1.6 mm 0.058 in or 1.5 mm 0.050 in or 1.3 mm 0.043 in or 1.1 mm The end of the saw power head has two oil holes, one on each side. These holes must match with the outlet of the oil pump. The pump sends the oil through the hole in the lower part of the gauge. Saw bar producers provide a large variety of bars matching different saws. Grease is pumped through a hole at the bar nose, typically each tank filling to keep the nose sprocket well lubricated. One or two bolts from the saw run through a guide slot. The clutch cover is put on top of the bar and it is secured through these bolts. The number of bolts is determined by the size of the saw. Different bar types are available:
Hemp juice is produced in a patented industrial procedure directly following harvest whereby the leafy upper part of the plant, including the flower heads, are being cold-pressed after harvest. These parts of the hemp plant have been entirely neglected so far in industrial hemp fabric production. Hence, through the procedure of pressing juice, a previously neglected highly valuable part of the plant is now being used for human consumption. All active ingredients remain fully intact without drying the hemp. The juice does not compete with the production of fibers and shives instead both add up to double revenue of the farmer. The average yield of hemp juice is approximately 3 tons per hectare. This newly developed production procedure allows for a significantly higher financial efficiency as well as sustainability in the cultivation of drug-free industrial hemp. Furthermore, the cold-pressing procedure preserves all of the plant-based active ingredients. There are two common harvesting procedures: "Cutting" the upper parts of the hemp plant or "stripping" the leaves off the uppermost part of the hemp plant. Both these procedures result in varying quantities of cannabinoids in the hemp juice. Consequently, the harvesting procedure in itself already influences the quality of the resulting hemp juice. If one only uses the uppermost, leafy part of the hemp plant for hemp juice production, the remaining part of the hemp plant can still be used for the industrial production of its fibers or any other industrial uses.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.